[ASND] Ascendis: Q3 2026 Earnings Preview on YORVIPATH Growth and Cash Flow

Ascendis Pharma is a Danish biopharmaceutical company that uses its proprietary TransCon long-acting technology to develop drugs for rare endocrine diseases, and it currently earns revenue from three products: YORVIPATH, SKYTROFA and YUVIWEL[1][2]. The company is scheduled to hold its earnings call on 2026-11-12 for the Third quarter 2026 (three months ended September 30, 2026)[3]. The latest disclosed quarter is the second quarter of 2026: total revenue was €339.3 million and product revenue was €314.9 million, up 105% year over year, including €252.1 million from YORVIPATH, €55.2 million from SKYTROFA and €7.6 million from YUVIWEL in its first quarter on the market[4][5]. Operating profit for the quarter was €220.5 million, of which €158.1 million came from the sale of a priority review voucher, and operating cash flow was €281.7 million[6][7]. On the second-quarter call, management reaffirmed its guidance for 2026 operating cash flow above €500 million[8]; on the first-quarter call it had said SKYTROFA revenue should stay stable through the year with seasonality similar to 2025[9]. Google Finance shows a third-quarter revenue estimate of €364.73 million[10], and FXEmpire's summary of 12 analysts puts third-quarter EPS at $0.95 on revenue of $372.37 million[11].

Three things matter most in this report. The first is whether YORVIPATH can keep growing sequentially once a one-time catch-up drops out: second-quarter revenue jumped from €196.9 million in the first quarter to €252.1 million[5], about €15 million of which management roughly estimated as the reversal of first-quarter one-time factors[12], leaving underlying sequential growth of about €40 million. Whether third-quarter revenue reaches €285 million will test whether the roughly 1,000 new U.S. patients a quarter that management describes are actually turning into paid revenue[13]. The second is whether YUVIWEL enrollments convert into revenue: through July 31 the company had more than 220 U.S. enrollments, with more than 65% approved for reimbursement[14], while the August 31 settlement with BioMarin requires a royalty of 20% on U.S. net sales[15], so the third quarter will be the first to show both the revenue trajectory and how that cost is booked. The third is cash flow excluding the voucher: first-half operating cash flow was €274.0 million, of which €158.1 million came from the voucher sale[6][7], and meeting the full-year guidance above €500 million requires about €113 million a quarter on average in the second half[8], so the third-quarter number will show whether gross profit from the three products can fund a still-growing commercial organization on its own.

Company Background and Business Structure

Ascendis is a commercial-stage rare-disease drugmaker built around a single technology platform. The company was incorporated in Denmark in 2006, is headquartered in Hellerup north of Copenhagen, and is led by President and CEO Jan Møller Mikkelsen; it completed its Nasdaq initial public offering of American Depositary Shares in February 2015[1], switched to direct Nasdaq trading of its ordinary shares on April 20, 2026[7], and was added to several Russell U.S. indexes, including the Russell 1000, after the close on June 26[4]. TransCon attaches a drug molecule to a carrier through a cleavable linker so that the unmodified drug is released in the body at a designed rate; YORVIPATH, for example, is a prodrug of parathyroid hormone (PTH) that, injected once a day, keeps blood hormone levels in the physiological range for 24 hours[16]. In September 2026, the company announced that it would regain the TransCon rights in metabolic and cardiovascular diseases previously licensed to Novo Nordisk, including once-monthly TransCon semaglutide, with no continuing financial obligations on either side[17].

Almost all revenue comes from three rare endocrine disease products. Product revenue in 2025 was €683.6 million, or 94.9% of total revenue of €720.1 million, with the remaining €36.6 million coming from services and clinical supply, licenses and milestones[18]. YORVIPATH is a once-daily parathyroid hormone replacement therapy, available for prescription in the U.S. since December 2024 and sold in Japan by partner Teijin since November 2025[19]; it generated €477.4 million in 2025 and €252.1 million in the second quarter of 2026[2][5]. SKYTROFA is a once-weekly growth hormone, available for prescription in the U.S. since October 2021[19], with revenue of €206.2 million in 2025 and €55.2 million in the second quarter of 2026[2][5]; YUVIWEL is a once-weekly achondroplasia drug that received U.S. FDA accelerated approval in February 2026[20], has been available for U.S. prescription since April[7], and generated €7.6 million in the second quarter[5].

The sales network is centered on the United States, which accounts for about three-quarters of revenue. In the U.S., the company's own team calls on physicians, a market access team works with payers, a patient support team helps with reimbursement approval and out-of-pocket assistance, and products are distributed through a specialty pharmacy network; in Europe the company runs direct organizations in the German-speaking countries, France and Benelux, Iberia, Italy, the Nordics, and the U.K. and Ireland, exclusive local distributors cover more than 75 other countries, and China and Japan are served through exclusive licensing partners[21]. By customer location, 2025 revenue was €546.4 million in the U.S., €120.9 million in Europe and €52.8 million in the rest of the world, with the U.S. accounting for 75.9% of the total[18].

The company does not build its own plants and relies on outside partners for manufacturing and part of its financing. Bachem supplies the PTH drug substance, Vetter fills YORVIPATH cartridges and assembles them with Ypsomed pens, Fujifilm and Lonza supply growth hormone material, Wacker supplies the CNP drug substance, and Vetter also makes YUVIWEL vials; the company says it currently has no other suppliers for these steps[22]. In 2024 it signed a synthetic royalty funding agreement with Royalty Pharma, receiving a $150 million upfront payment in exchange for 3.0% of net U.S. YORVIPATH revenue[23], and the carrying amount of its royalty funding liabilities was €301.8 million at the end of June 2026[6]; the income statement also includes a share of profit or loss from associates, which was a loss of €10.3 million in the first quarter of 2026[24].

Financial History and Current Position

2025 was the year YORVIPATH doubled revenue while the company was still losing money. According to the 2025 20-F, total revenue rose from €266.7 million in 2023 to €363.6 million in 2024 and €720.1 million in 2025[18]; YORVIPATH revenue grew from €28.7 million in 2024 to €477.4 million, while SKYTROFA edged up from €197.0 million to €206.2 million[2]. Gross profit in 2025 was €625.2 million, an 86.8% gross margin, on cost of sales of €94.9 million[25][26]; research and development expenses were €303.6 million, selling, general and administrative expenses were €457.9 million, the operating loss was €136.3 million (versus a €278.8 million loss in 2024), and the net loss was €228.0 million[1][25].

Cash generation improved in 2025, but the balance sheet remained weak. Operating cash flow for the year was €53.9 million, the company's first positive full year, compared with an outflow of €306.2 million in 2024[25]; year-end cash and cash equivalents were €616.0 million[27], and shareholders' equity was negative €162.8 million[1].

In the first quarter of 2026 the company reached an operating profit, but net income came mainly from a tax item. Revenue was €246.6 million, the gross margin was 92.9%, SG&A was €145.2 million and operating profit was €24.8 million; net profit was €629.3 million, mainly because the company recognized €679 million of previously unrecognized deferred tax assets[24], and recognized deferred tax assets stood at €690.4 million at March 31[28]. YORVIPATH revenue was €196.9 million in the first quarter, and the company attributed the sequential slowdown to normal U.S. seasonality, a temporary increase in patients on free drug and a one-time impact in its Europe Direct markets[20].

The second-quarter income statement combined real growth with a one-time gain. Revenue was €339.3 million, gross profit was €311.6 million at a 91.8% margin, operating profit was €220.5 million and net profit was €207.0 million[6]; R&D expenses were about €76 million and SG&A about €173 million[29]. Net income of €158.1 million from the priority review voucher sale (sold for $187.5 million) was booked as other operating income and included in operating cash flow[7]; excluding it, operating profit was about €62.4 million, a margin of about 18.4%.

The second-quarter balance sheet was transformed by the conversion of the convertible notes. On May 6 the company completed its redemption process and all $575 million of 2028 convertible notes converted[30], turning shareholders' equity from negative €162.8 million at the end of 2025 into €1,436.5 million at the end of June[4]. Operating cash flow was €274.0 million for the first half and €281.7 million for the second quarter alone[6]; cash and cash equivalents were €812.3 million at the end of June after €56 million was used in the second quarter for share repurchases and the net settlement of restricted stock units[30]. The company announced a $120 million repurchase program in January[28], and in September the board authorized repurchases of up to $400 million[31].

Operating Model

Revenue is driven by the number of paying patients on each product and the net price. Total revenue equals product revenue plus collaboration and service revenue, and product revenue equals paying patients on therapy multiplied by the net price after rebates and free drug; in the second quarter of 2026, product revenue was €314.9 million and non-product revenue was about €24.4 million[5][6]. For YORVIPATH, the chain runs from a U.S. endocrinologist's prescription to patient enrollment, free drug while insurance approval is pending, and then specialty pharmacy dispensing and paid therapy[21][20], so enrollments lead revenue, and the share on free drug and the speed of approvals determine the length of the lag. U.S. revenue is priced in dollars and translated into euros, and currency translation reduced reported revenue by €7.6 million year over year in the second quarter and by €28.0 million in the first half[32].

Operating profit depends mainly on whether revenue can absorb the cost of the commercial organization. Operating profit equals revenue times the gross margin, minus R&D and SG&A, plus other operating income; the drugs are made by contract manufacturers at low unit cost, and the second-quarter gross margin was 91.8%[6], so the main costs are the U.S. and European commercial teams and R&D, about €173 million and €76 million respectively in the second quarter[29]. The more patients on therapy, the more thinly fixed sales and patient support costs are spread and the higher the operating margin; the new cost comes from YUVIWEL, on which royalties of 20% of U.S. net sales and 18% in the EU, South Korea and Brazil are payable to BioMarin through May 20, 2030[15].

Operating cash flow is affected by working capital and one-time items beyond profit. Operating cash flow roughly equals operating profit plus non-cash items such as share-based compensation, plus or minus working capital in receivables, inventory and rebate accruals, minus interest and taxes; it was €53.9 million in 2025[25] and €274.0 million in the first half of 2026, made up of about negative €7.7 million in the first quarter and €281.7 million in the second[6]. The company has tax loss carryforwards with a gross amount of €1,954.6 million, which management judges future taxable profits can absorb, so cash taxes remain low for now[28]; the main uses of cash are share repurchases and R&D.

Industry and Competitive Position

The hypoparathyroidism market that YORVIPATH serves currently lacks a comparable replacement therapy. The company estimates about 70,000 to 90,000 U.S. patients, including 4,000 to 5,000 previously treated with PTH therapy[16]; Takeda's NATPARA was approved in the U.S. in 2015 as an adjunct to calcium and vitamin D, recalled in the U.S. in 2019, and discontinued globally by the end of 2024, and its Special Use Program closed permanently on December 31, 2025[1]. Calcilytix (a BridgeBio company), Entera Bio, MBX Biosciences, Amolyt and others are still developing hypoparathyroidism therapies[33], so YORVIPATH currently competes mainly with conventional calcium and vitamin D regimens and with drugs in development.

YUVIWEL enters a market with a strong incumbent. BioMarin's VOXZOGO is approved in more than 40 markets, BioMarin is developing a long-acting CNP drug called BMN 333, and companies including BridgeBio's QED also have achondroplasia programs[33]; VOXZOGO is injected once a day, while YUVIWEL is given once a week[34]. On August 31, 2026 the two companies settled: BioMarin granted a non-exclusive worldwide license and dismissed all proceedings, and Ascendis pays royalties on net sales of navepegritide-related products of 20% in the U.S. and 18% in the EU, South Korea and Brazil through May 20, 2030[15].

SKYTROFA faces stiffer competition in long-acting growth hormone. Novo Nordisk's once-weekly SOGROYA is approved for children and adults in the U.S., Japan, Europe and elsewhere, and Pfizer's once-weekly NGENLA, developed with OPKO, is approved for pediatric growth hormone deficiency in more than 40 countries[35]. The disclosures cited here describe the competitive landscape only; the company does not report market shares or comparable competitor revenue, so changes in SKYTROFA's share cannot be quantified.

Core Debates

Can roughly 1,000 new U.S. patients a quarter keep YORVIPATH growing strongly in the third quarter?

Growth in paying YORVIPATH patients is the main source of Ascendis's revenue and cash flow. The drug generated €477.4 million in 2025, or 66.3% of total revenue[2][18]; second-quarter 2026 revenue was €252.1 million versus €103.0 million a year earlier, roughly 80% of the quarter's product revenue[5]. The U.S. has about 70,000 to 90,000 patients[16]; more than 5,300 had been prescribed the drug by the end of 2025 and more than 6,300 had enrolled by the end of March 2026[19][20], and management's full-year cash flow guidance and its €5 billion 2030 revenue target rely mainly on continued growth of this drug[8].

There are two readings of the second-quarter rebound, and the third quarter can separate them. First-quarter revenue was €196.9 million, which the company attributed to seasonality, more patients on free drug and a one-time Europe Direct factor, and management said on the call that its roughly €15 million estimate of the impact was rough[20][12]; revenue then recovered to €252.1 million, and management said key indicators, including a steady ~1,000 new U.S. patients a quarter, remained consistent[13], which implies that about €40 million of the €55.2 million sequential increase remains after removing the catch-up. The alternative reading is that part of the second-quarter jump came from first-quarter free-drug patients converting to paid therapy together and from back payments as reimbursement improved; without a similar catch-up in the third quarter, revenue growth would fall well short of €40 million even if enrollments hold steady. The company does not split YORVIPATH revenue between the U.S. and the rest of the world, and currency cut second-quarter revenue by €7.6 million year over year[32], which makes it hard for outsiders to isolate growth in paying U.S. patients.

The debate reaches the income statement through paid conversion. The chain runs from a U.S. endocrinologist's prescription to enrollment, free drug while insurance approval is pending, specialty pharmacy dispensing and payment, and finally YORVIPATH revenue; the more patients on therapy, the more thinly fixed sales and patient support costs are spread and the higher the operating margin. Conversely, if new paying patients lag enrollments, sequential revenue growth will slow before enrollments do, and because the company does not disclose paid conversion, discontinuation or the free-drug share each quarter, this part cannot be resolved from the outside.

The third quarter should be judged on revenue, enrollments and management's explanation. Confirmation would be YORVIPATH revenue of at least €285 million, a reaffirmed pace of about 1,000 new U.S. enrollments a quarter with an updated cumulative count, and a clear account of how currency, free drug and ex-U.S. markets affected the sequential change; revenue below €265 million, flat or falling sequential revenue caused by discontinuations, free drug or rebates rather than currency, or quarterly enrollments clearly below about 1,000 would weaken the view that new patients are steadily turning into revenue.

How quickly can YUVIWEL enrollments turn into revenue, and how much will the BioMarin royalty take?

YUVIWEL is the company's third growth product, but the settlement cuts into its margin from the start. It enters an achondroplasia market already held by BioMarin's VOXZOGO, with the advantage of once-weekly rather than once-daily dosing[34]; revenue in its first quarter on the market was €7.6 million[5], still small, but management's 2030 revenue target needs a second and third product to carry growth[8]. The August 31 settlement ended all litigation with BioMarin at the cost of paying BioMarin 20% of U.S. net sales through May 20, 2030[15].

Early enrollment has been quick, but its sources and conversion pace remain unclear. Through July 31 there were more than 220 U.S. enrollments from more than 100 prescribers, with more than 65% approved for reimbursement[14]; management said new patients come from three groups, those switching from existing therapy, those returning after discontinuing and first-time patients[36], and believes most come from previously untreated or lapsed patients, while acknowledging that it does not track the exact split[8]. The alternative reading is that early enrollments are dominated by VOXZOGO switchers and that growth will slow once that pool is exhausted. In the EU, the CHMP has issued a positive opinion and the company plans a first launch in Germany in the first quarter of 2027 if the European Commission approves[37], and the COMP has recommended maintaining orphan designation, which would bring 10 years of market exclusivity once the European Commission adopts it[38].

Revenue and the royalty cost will enter the third-quarter income statement together. The chain runs from a pediatric endocrinologist's prescription to enrollment, insurance approval and weekly dosing, and finally YUVIWEL revenue; royalties of 20% of U.S. net sales and 18% in the EU, South Korea and Brazil are paid to BioMarin[15]. Because the settlement came after the second quarter ended, nothing was accrued for that quarter; if all €7.6 million of its revenue was U.S. revenue, the terms would imply about €1.5 million. Second-quarter revenue may also include initial stocking, so third-quarter growth need not track enrollments, and the company has not yet disclosed which line the royalty will be booked in or whether it will be accrued retroactively.

The third quarter offers four readings. Confirmation would be YUVIWEL revenue of €15 million or more, monthly new enrollments of about 50 after July 31 with reimbursement approval above 65%, disclosure of the royalty's accounting line and any retroactive amount, and European Commission approval on schedule in the fourth quarter[37]; third-quarter revenue below €7.6 million would signal blocked paid conversion or second-quarter stocking, and a delayed EU decision that pushes back the German launch would reduce YUVIWEL's role as the next growth driver.

Excluding the one-off voucher sale, can Ascendis's cash flow support its €500 million full-year target?

Profit and cash flow excluding one-time items are the right test of the three products' earning power. The company first reached positive full-year operating cash flow only in 2025, at €53.9 million[25], and guides to more than €500 million in 2026[8]; but €158.1 million of second-quarter operating profit of €220.5 million came from selling the priority review voucher it received with YUVIWEL's approval[7], and first-quarter net profit of €629.3 million came mainly from one-time recognition of deferred tax assets[24]. Only after removing these items can one see whether the three products' gross profit covers an expanding commercial organization and where the money for the $400 million repurchase program comes from[31].

Underlying profitability improved in the second quarter, but quarterly cash flow is volatile. First-half operating cash flow was €274.0 million, about negative €7.7 million in the first quarter and €281.7 million in the second[6], or about €123.6 million in the second quarter excluding the voucher; the second-quarter gross margin was 91.8%, and SG&A of about €173 million rose roughly 60% year over year, slower than the 105% growth in product revenue[29][4], while cash was €812.3 million at the end of June and the convertible notes had been fully settled[30]. The alternative reading holds that quarterly cash flow is heavily affected by working-capital timing such as rebate accruals, as the negative first quarter shows, and the company's 6-K notes that working capital changes were an overall outflow of €95.8 million in the first half[32]; in addition, the third quarter will start to carry the royalty owed to BioMarin[15].

The financial transmission runs from gross profit to repurchase capacity. Product revenue times a gross margin of about 92%, minus R&D and SG&A, gives operating profit; adding back non-cash items and deducting working capital changes, interest and taxes gives operating cash flow, which then funds repurchases (the $120 million program in January[28] and the up to $400 million program in September[31]) and R&D. Of first-half net profit of €836.3 million, €679.6 million came from the initial recognition of deferred tax assets, and €158.1 million of operating profit came from the voucher[6][7]; neither will recur, so the third quarter is the first relatively clean reading.

The third quarter should be judged on cash flow, underlying profit and cost discipline. Confirmation would be operating cash flow of about €113 million, operating profit excluding one-time items above the second quarter's roughly €62.4 million, sequential SG&A growth slower than product revenue growth, and a maintained full-year operating cash flow guide above €500 million alongside progress on repurchases; operating cash flow below €60 million, a cut to the full-year guidance, or SG&A growing faster than product revenue and pulling operating profit down would weaken the view that product gross profit can support the cash flow target.

Risks and Falsifiers

Supply chain concentration is the most direct risk of an operating disruption. The drug substance and finished product for all three products depend on one or a few contract manufacturers, YORVIPATH's drug substance comes only from Bachem and its finished product is filled by Vetter, and the company says in its 20-F that it currently has no other suppliers for these steps[22]; all €683.6 million of 2025 product revenue depended on these manufacturers[2], and a quality or capacity problem at any one of them would interrupt supply directly. Disclosure of an approved second supplier, or quarterly reports that continue to show no shortages, recalls or supply constraints, would reduce this risk.

U.S. drug pricing and reimbursement policy can push net prices down. The company participates in the Medicaid Drug Rebate Program and the 340B drug pricing program, and the Inflation Reduction Act requires Medicare price negotiation for certain drugs[1], while the U.S. accounted for 75.9% of 2025 revenue, or €546.4 million[18]; at 2025 levels, each 5% decline in net price would cut revenue by about €27 million, nearly all of which would fall to operating profit. If quarterly reports show YORVIPATH revenue growth keeping pace with enrollment growth and the company flags no net price decline, this risk has not materialized.

Slower conversion of U.S. demand to paid therapy would show up in revenue before enrollments. YORVIPATH depends on U.S. insurance approvals and specialty pharmacy distribution, free drug, commercial insurance and government rebates all weigh on its net price, and it accounted for 66.3% of 2025 revenue[2][18]; every €20 million that third-quarter revenue falls short of the €285 million confirmation line equals about one-third of second-quarter operating profit excluding the voucher (about €62.4 million)[5][7]. Third-quarter YORVIPATH revenue of at least €285 million, together with a reaffirmed pace of about 1,000 new enrollments a quarter[13], would support the current view.

YUVIWEL faces both competition and royalty costs. VOXZOGO is approved in more than 40 markets, BioMarin is developing a long-acting CNP, and BridgeBio and others are advancing achondroplasia programs[33]; after the settlement, royalties of 20% in the U.S. and 18% in the EU, South Korea and Brazil directly reduce YUVIWEL's gross profit through May 20, 2030, about €1.5 million on second-quarter revenue[15]. If YUVIWEL quarterly revenue keeps doubling and the EU approves on time with 10 years of orphan exclusivity[38], this risk would ease considerably.

Earnings quality depends on one-time items that will not recur. Of first-half 2026 net profit of €836.3 million, €679.6 million came from the initial recognition of deferred tax assets, and €158.1 million of operating profit came from the voucher sale[6][7]; recognition of the deferred tax assets rests on YORVIPATH growth forecasts that management keeps under review, €690.4 million had been recognized at March 31, and any write-down would hit the income statement directly[28]. Cash was €812.3 million at the end of June[30]; if third-quarter operating cash flow is below €60 million, the full-year target above €500 million would require more than about €166 million in the fourth quarter[8], while third-quarter operating cash flow of at least about €113 million and rising underlying operating profit would ease this risk.

What to Watch Next

• YORVIPATH conversion: third-quarter revenue against the second quarter's €252.1 million (first quarter €196.9 million). At least €285 million confirms; below €265 million, or flat sequential revenue caused by discontinuations, free drug or rebates, falsifies.
• YORVIPATH enrollments: whether management reaffirms about 1,000 new U.S. enrollments a quarter and updates the cumulative count from more than 6,300 at March 31. A clear shortfall falsifies.
• YUVIWEL launch: third-quarter revenue against €7.6 million, monthly new enrollments after the more than 220 reported through July 31, and reimbursement approval above 65%. €15 million or more confirms; below €7.6 million falsifies.
• BioMarin royalty and EU approval: the accounting line and any retroactive amount for the 20% U.S. and 18% EU, South Korea and Brazil royalty, and the European Commission decision due in the fourth quarter. On-time approval and clear booking confirm; a delay that pushes back the German launch falsifies.
• Cash flow excluding one-time items: third-quarter operating cash flow against the second quarter's €281.7 million (about €123.6 million without the voucher) and the first half's €274.0 million. About €113 million or more with the full-year guide above €500 million maintained confirms; below €60 million or a guidance cut falsifies.
• Underlying profit and SG&A: operating profit excluding one-time items against about €62.4 million, and SG&A against about €173 million. Higher underlying profit with SG&A growing slower than product revenue confirms; SG&A outgrowing revenue and falling profit falsifies.

Conclusion

Ascendis's business runs on a clear chain: U.S. prescriptions create enrollments, enrollments become paid therapy after insurance approval, and paying patients at a gross margin of about 92% spread the fixed cost of the commercial organization. In 2025 the company generated €720.1 million of revenue and its first positive full-year operating cash flow[18][25]; in the second quarter of 2026 product revenue rose 105% year over year, cash reached €812.3 million at the end of June, and equity turned positive after the notes converted[4][30]. But second-quarter operating profit and first-half net profit were both lifted by the voucher and deferred tax assets, and second-quarter operating profit excluding the voucher was about €62.4 million[7]; the central unresolved relationship is whether roughly 1,000 new U.S. patients a quarter keep turning into YORVIPATH revenue, whether YUVIWEL enrollments can become a second growth source after the 20% royalty, and whether the two together can produce about €113 million of operating cash flow a quarter in the second half.

Since the latest results, independent outside analysis has focused on the YUVIWEL settlement with BioMarin. In an August 31 article, Mandy Jackson of Scrip (Citeline) argued that once-weekly YUVIWEL will erode sales of BioMarin's blockbuster VOXZOGO, that the double-digit royalties BioMarin secured in the settlement could partly offset losses from patients switching from daily to weekly injections, and that BridgeBio may also soon enter the achondroplasia market[34]. That view treats VOXZOGO switchers as YUVIWEL's main source of patients, which differs from management's statement that most come from previously untreated or lapsed patients[8], and third-quarter enrollment and revenue growth can test which reading is closer to the facts; it also signals that the royalty and potential new competitors will both reduce YUVIWEL's profit contribution. This is a single outside interpretation, not a measure of overall market opinion; other coverage between August 13 and November 11 consisted mostly of share-price reports, brokers revising their views and reprints of company announcements, so the YORVIPATH and cash flow debates currently lack an independent outside reference.

The combination that would materially strengthen the current view is third-quarter YORVIPATH revenue of at least €285 million with U.S. enrollments holding at about 1,000 a quarter, YUVIWEL revenue of €15 million or more with reimbursement approval staying above 65%, operating profit excluding one-time items above about €62.4 million and operating cash flow of about €113 million, and a maintained full-year cash flow guide above €500 million. Conversely, YORVIPATH revenue below €265 million because of discontinuations, free drug or rebates, YUVIWEL revenue below the second quarter's €7.6 million, or operating cash flow below €60 million accompanied by a guidance cut would clearly weaken the current view.

Sources

[1] ASND 20-F filed 2026-02-11 · 2026-02-11 · 20-F · https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm

[2] ASND 20-F filed 2026-02-11 product revenue · 2026-02-11 · 20-F · https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm

[3] Drillr earnings calendar 2026-11-10 ASND Q3 2026 · 2026-11-10 · Drillr earnings calendar

[4] ASND 6-K filed 2026-08-13 Q2 2026 results · 2026-08-13 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm

[5] ASND 6-K filed 2026-08-13 Q2 2026 product revenue table · 2026-08-13 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000161204226000016/asnd-20260630.htm

[6] ASND 6-K filed 2026-08-13 Q2 2026 financial highlights · 2026-08-13 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000161204226000016/asnd-20260630.htm

[7] ASND 6-K filed 2026-08-13 Q2 2026 PRV sale · 2026-08-13 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000161204226000016/asnd-20260630.htm

[8] ASND Q2 2026 earnings call 2026-08-13 · 2026-08-13 · earnings-call · https://investors.ascendispharma.com/events-and-presentations

[9] ASND Q1 2026 earnings call 2026-05-07 · 2026-05-07 · earnings-call · https://investors.ascendispharma.com/events-and-presentations

[10] Google Finance ASND 2026-11-10 Q3 2026 revenue estimate · 2026-11-10 · Google Finance(汇总分析师预期) · https://www.google.com/finance/quote/ASND:NASDAQ

[11] FXEmpire ASND earnings page 2026-11-10 Q3 2026 consensus · 2026-11-10 · FXEmpire(12 位分析师汇总) · https://www.fxempire.com/stocks/asnd/earnings

[12] ASND Q1 2026 earnings call 2026-05-07 one-time impact · 2026-05-07 · earnings-call · https://investors.ascendispharma.com/events-and-presentations

[13] ASND Q2 2026 earnings call 2026-08-13 YORVIPATH demand · 2026-08-13 · earnings-call · https://investors.ascendispharma.com/events-and-presentations

[14] ASND 6-K filed 2026-08-13 Q2 2026 YUVIWEL launch · 2026-08-13 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm

[15] ASND 6-K filed 2026-08-31 BioMarin settlement · 2026-08-31 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000119312526376733/d139239d6k.htm

[16] ASND 20-F filed 2026-02-11 hypoparathyroidism prevalence · 2026-02-11 · 20-F · https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm

[17] ASND 6-K filed 2026-09-15 Novo Nordisk rights return · 2026-09-15 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000119312526390877/d183438d6k.htm

[18] ASND 20-F filed 2026-02-11 revenue by geography · 2026-02-11 · 20-F · https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm

[19] ASND 20-F filed 2026-02-11 YORVIPATH U.S. patients · 2026-02-11 · 20-F · https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm

[20] ASND 6-K filed 2026-05-07 Q1 2026 results · 2026-05-07 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000119312526210386/d121855dex991.htm

[21] ASND 20-F filed 2026-02-11 commercial model · 2026-02-11 · 20-F · https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm

[22] ASND 20-F filed 2026-02-11 manufacturing · 2026-02-11 · 20-F · https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm

[23] ASND 20-F filed 2026-02-11 royalty funding · 2026-02-11 · 20-F · https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm

[24] ASND 6-K filed 2026-05-07 Q1 2026 income statement · 2026-05-07 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000119312526210386/d121855dex991.htm

[25] ASND 20-F filed 2026-02-11 financial highlights · 2026-02-11 · 20-F · https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm

[26] ASND 20-F filed 2026-02-11 cost of sales · 2026-02-11 · 20-F · https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm

[27] ASND 20-F filed 2026-02-11 liquidity · 2026-02-11 · 20-F · https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm

[28] ASND 6-K filed 2026-05-07 Q1 2026 deferred tax · 2026-05-07 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000161204226000005/asnd-20260331.htm

[29] ASND 6-K filed 2026-08-13 Q2 2026 operating expenses · 2026-08-13 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm

[30] ASND 6-K filed 2026-08-13 Q2 2026 cash and convertible notes · 2026-08-13 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm

[31] ASND 6-K filed 2026-09-15 share repurchase · 2026-09-15 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000119312526390874/d52763d6k.htm

[32] ASND 6-K filed 2026-08-13 Q2 2026 currency · 2026-08-13 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000161204226000016/asnd-20260630.htm

[33] ASND 20-F filed 2026-02-11 competition · 2026-02-11 · 20-F · https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm

[34] Scrip 2026-08-31 BioMarin Yuviwel royalties · 2026-08-31 · Scrip(Citeline) · https://insights.citeline.com/scrip/business/legalandip/biomarin-secures-double-digit-yuviwel-royalties-in-settlement-with-ascendis-A57GJOU4PFG3VAOSQYMF5GD4WE/

[35] ASND 20-F filed 2026-02-11 growth hormone competition · 2026-02-11 · 20-F · https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm

[36] ASND Q2 2026 earnings call 2026-08-13 YUVIWEL uptake · 2026-08-13 · earnings-call · https://investors.ascendispharma.com/events-and-presentations

[37] ASND 6-K filed 2026-10-16 CHMP opinion · 2026-10-16 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000119312526423938/d167361d6k.htm

[38] ASND 6-K filed 2026-11-06 orphan designation · 2026-11-06 · 6-K · https://www.sec.gov/Archives/edgar/data/1612042/000119312526451904/d117407d6k.htm